Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability

American Journal of Neuroradiology

Volumn 18, Issue 8, 1997, Pages 1549-1556

  Filippi, Massimo ^a,b   Rossi, Paolo ^a   Campi, Adriana ^a   Colombo, Bruno ^a   Pereira, Clodoaldo ^a   Comi, Giancarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Brain, magnetic resonance; Sclerosis, multiple

Indexed keywords

CLINICAL ARTICLE; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISABILITY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING;

ACTIVITIES OF DAILY LIVING; ADULT; BRAIN; COMPUTER SYSTEMS; CONTRAST MEDIA; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; SOFTWARE;

EID: 0031546005     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (39)

1. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319-334
2. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in multiple sclerosis. Ann Neurol 1993;34:661-669
3. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688
4. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increased the sensitivity of MRI in detecting disease activity in MS. Brain 1993;116:1077-1094
5. Filippi M, Miller DH. Magnetic resonance imaging in the differential diagnosis and monitoring of the treatment of multiple sclerosis. Curr Opin Neurol 1996;9:176-186
6. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging to monitor disease activity in multiple sclerosis. Ann Neurol 1992;32:758-766
7. Nauta JJP, Thompson AJ, Barkhof F, Miller DH. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-group and crossover design. J Neurol Sci 1994;122:6-14
8. Miller DH. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994;36:S91-S94
9. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
10. Lublin FD, Reingold SC, the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911
11. Lhermitte F, Marteu R, Gazengel J, Dordain G, Deloche G. The frequency of relapse in multiple sclerosis: a study based on 245 cases. J Neurol 1973;205:47-59
12. Broman T, Andersen O, Bergmann I. Clinical studies on multiple sclerosis: presentation of an incidence material from Gothenburg. Acta Neurol Scand 1981;63:6-33
13. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452
15. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MR changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-1222
16. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55:450-453
17. Barkhof F, Filippi M, Miller DH, et al. Interobserver variation in reporting gadolinium-enhanced lesions in multiple sclerosis. J Neurol 1996;243(Suppl 2):S18
18. Filippi M, Barkhof F, Bressi S, et al. Intrerater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans in patients with multiple sclerosis. J Neurol 1996; 243(Suppl 2):S70
19. Filippi M, Horsfield MA, Bressi S, et al. Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis: a comparison of techniques. Brain 1995;118:1593-1600
20. Filippi M, Yousry T, Baratti C, et al. Quantitative assessment of MRI lesion load in multiple sclerosis: a comparison of conventional spin-echo with fast-fluid attenuated inversion recovery. Brain 1996;119:1349-1355
21. Rovaris M, Filippi M, Calori G, et al. Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol 1997;244:266-270
22. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow up study. Neurology 1995;45:256-260
23. Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15-19
24. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing lesions in patients with multiple sclerosis. Ann Neurol 1993;33:480-489
25. Stone LA, Smith ME, Albert PS, et al. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology 1995;45:1122-1126
26. Paty DW, Li DBK, Oger JJF, et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 1994;36:S95-S96
27. Grossmann RI, Lenkinski RE, Ramer KN, Gonzales-Scarano F, Cohen JA. MR proton spectroscopy in multiple sclerosis. AJHR Am J Neuroradiol 1992;13:1535-1543
28. Bakker DA, Ludwin SK. Blood-brain barrier permeability during cuprizone-induced demyelination: implications for pathogenesis of immune-mediated demyelination diseases. J Neurol Sci 1987; 78:125-137
29. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994;117;759-765
30. Filippi M, Campi A, Martinelli V, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59:540-544
31. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with multiple sclerosis. Neurology 1996;46:379-384
32. Filippi M, Capra R, Campi A, et al. Triple dose of gadolinium-DTPA and delayed scanning in benign multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:526-530
33. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
34. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319-334
35. Losseff NA, Kingsley DPE, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996;1:218-222
36. Filippi M, Campi A, Colombo B, et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996;243:502-505
37. Losseff NA, Webb SL, O'Riordan JI, Miller DH, Thompson AJ. Spinal cord atrophy and disability in multiple sclerosis: a new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701-708
38. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with disability in multiple sclerosis. Ann Neurol 1994;36:62-67
39. van Walderveen MAA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995;45:1684-1690